From in vivo investigation, we observed a significantly lower serum CXCL10 in subjects taking iloprost, either alone (260.3 ± 45.3 pg/mL, p < 0.001) or in combination with disease-modifying anti-rheumatic drugs (DMARDs) or corticosteroids (CCs) (552.3 ± 198.3 pg/mL and 407.4 ± 76.5 pg/mL, respectively, p < 0.01), as compared with SSc subjects without therapy (806.3 ± 110.6 pg/mL) (Figure 4). The gene discussed is CXCL10; the disease is systemic sclerosis.